Cancer Biomarkers Market Growth Driven by Precision Oncology Advancements

The global cancer biomarkers market was valued at USD 26.92 billion in 2025 and is anticipated to reach USD 65.30 billion by 2033, expanding at a CAGR of 11.82% from 2026 to 2033. Market growth is being driven by the increasing prevalence of cancer worldwide, rising demand for early disease detection, and the growing adoption of personalized treatment approaches. Continuous advancements in molecular diagnostics and biomarker-based testing are enabling healthcare providers to improve treatment outcomes and enhance patient care.

Key Market Trends & Insights

• North America accounted for the largest share of the global market, representing 41.61% in 2025.
• The U.S. cancer biomarkers market is expected to witness substantial growth throughout the forecast period.
• By type, the lung cancer segment dominated the market with a 21.73% share in 2025.
• By biomolecule, genetic biomarkers held the largest market share in 2025.
• By application, the diagnostics segment led the market in 2025.
• By technology, polymerase chain reaction (PCR)-based technologies accounted for the largest share in 2025.
• Asia Pacific is projected to be the fastest-growing regional market during the forecast period.

Market Size & Forecast

Metric	Value
Market Size (2025)	USD 26.92 Billion
Projected Market Size (2033)	USD 65.30 Billion
CAGR (2026-2033)	11.82%
Largest Regional Market (2025)	North America
Fastest Growing Region	Asia Pacific

The increasing integration of genomics, proteomics, next-generation sequencing (NGS), and molecular diagnostic technologies is transforming the cancer biomarker landscape. Healthcare institutions, including hospitals and diagnostic laboratories, are increasingly implementing biomarker-based testing to support precision medicine and improve clinical outcomes. In addition, favorable government initiatives and growing investments in cancer research are accelerating market expansion. The rising demand for targeted therapies continues to create significant opportunities for biomarker development and commercialization across global healthcare systems.

Download a free sample copy of the Cancer Biomarkers Market report to understand detailed coverage and inclusions in the final report

Cancer remains one of the most significant public health challenges worldwide and continues to be a leading cause of mortality. According to findings published in The Lancet in September 2025 from the Global Burden of Disease (GBD) 2023 study, cancer burden was evaluated across 47 cancer types in 204 countries and territories between 1990 and 2023, with forecasts extending through 2050. The study identified cancer as the second-leading cause of death globally in 2023, following cardiovascular diseases, with annual cancer-related deaths projected to surpass 18 million by 2050.

Additional estimates released by the Institute for Health Metrics and Evaluation in September 2025 reported approximately 18.5 million new cancer cases and more than 10.4 million cancer-related deaths globally. These cases contributed to nearly 271 million disability-adjusted life years (DALYs) lost worldwide. Nearly 60% of both cancer cases and cancer-related deaths occurred in low- and middle-income countries, underscoring disparities in healthcare access and disease management. Lung cancer and colorectal cancer remained the first and second leading causes of cancer mortality, respectively. The growing patient population requiring diagnosis, treatment selection, and disease monitoring is expected to accelerate adoption of biomarker technologies and support long-term market growth.

Looking for more specific insights? Customize this report to suite your business needs

Research and development activities continue to play a pivotal role in advancing the cancer biomarkers industry. Increased government funding and institutional support are accelerating biomarker discovery, validation, and commercialization efforts. The National Cancer Institute (NCI) remains one of the most influential organizations driving oncology research through collaborations with academic institutions, healthcare organizations, and global research networks.

According to NCI data published in July 2025, the institute managed funding totaling USD 7.2 billion, with 43.3% of its obligated budget allocated to Research Project Grants. These investments are contributing to advancements in precision oncology, immuno-oncology, liquid biopsy technologies, and biomarker-based diagnostic solutions. As a result, ongoing research initiatives are expected to strengthen the clinical utility of cancer biomarkers and expand their applications across cancer detection, prognosis, treatment selection, and disease monitoring.

Key Cancer Biomarkers Company Insights

The cancer biomarkers market features a mix of established diagnostic companies and emerging precision oncology firms competing through technological innovation, product development, and strategic partnerships. Leading market participants are investing heavily in advanced technologies such as next-generation sequencing (NGS), immunohistochemistry (IHC), multiplex assays, and companion diagnostics to enhance their competitive positioning.

Explore Grand View Horizon to see global and regional level statistics related to the Cancer Biomarkers Market

Collaborations between diagnostic companies, pharmaceutical manufacturers, and research institutions are supporting the development of biomarker-driven therapies and precision medicine solutions. Emerging companies are increasingly focusing on liquid biopsy platforms and PCR-based biomarker assays to broaden clinical applications and improve accessibility. Key competitive factors include assay accuracy, clinical validation, turnaround time, scalability, and seamless integration into oncology workflows.

Key Cancer Biomarkers Companies

• Abbott
• QIAGEN
• Thermo Fisher Scientific
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Agilent Technologies, Inc.
• Merck & Co. Inc.
• Hologic, Inc.
• Sino Biological Inc.

Conclusion

The cancer biomarkers market is positioned for strong growth through 2033, driven by rising global cancer incidence, increasing emphasis on early diagnosis, and the growing adoption of precision medicine. Technological advancements in genomics, molecular diagnostics, NGS, and liquid biopsy platforms are enhancing the effectiveness of biomarker-based testing across oncology applications. Continued research funding, supportive government initiatives, and expanding use of targeted therapies are expected to further strengthen market development. As healthcare systems increasingly focus on personalized treatment and improved patient outcomes, cancer biomarkers will remain a critical component of modern cancer diagnosis, prognosis, and therapeutic decision-making.

Looking for a report customized to your requirements? Explore our Custom Research Offering

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments.
• Extended forecast timelines for long-term planning.
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments.
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making

And much more…

Browse our new services – Grand View Brainshare